Shiv Kumar Srivastava, Antesh Kumar Jha*, Mahesh Prasad
Kamla Nehru Institute of Management and Technology, NH-330 Ayodhya-Prayagraj Highway Faridipur, Sultanpur-228119, UP, India
*Address for Corresponding author
Dr. Antesh Kumar Jha
Kamla Nehru Institute of Management and Technology
NH-330 Ayodhya Prayagraj Highway, Faridipur, Sultanpur-228119, UP, India
Abstract
Biopharmaceutical Classification system (BCS) becomes fundamental to contemporary oral medication development by mechanistically correlating drug solubility and intestinal permeability to systemic exposure. Based on their dissolving behavior and membrane transport characteristics that affect oral absorption kinetics and formulation strategy, BCS divides active medicinal substances into four classes. For immediate-release medicines, this paradigm helps formulation scientists anticipate absorption constraints and choose strategies to maximize bioavailability and in vitro performance. Moreover, regulatory agencies globally have incorporated BCS principles into guidance documents, allowing certain drugs that meet defined solubility and permeability thresholds to qualify for in vitro biowaivers in place of in vivo bioequivalence studies, thereby reducing cost and time in regulatory submission pathways. The ICH M9 guideline, which was recently harmonized, significantly improves categorization criteria, such as comparative permeability and solubility across pertinent pH ranges, creating uniform worldwide standards for BCS-based biowaivers for Class I and III medications. Alongside regulatory evolution, advances in PBPK (physiologically-based pharmacokinetic) modeling and biorelevant dissolution assessment have enhanced the predictive value of the BCS by simulating in vivo absorption scenarios, supporting early decision-making during candidate selection and formulation optimization. Despite these gains, obstacles remain-particularly for poorly soluble, poorly permeable compounds (BCS Class II and IV) and for ensuring that excipient variations do not influence absorption outcomes. Continued improvement of BCS criteria and integration with developing computational and dissolving approaches will enhance its utility in regulatory science and product development, supporting efficient, cost-effective delivery of safe and effective oral medications.
Keywords: Biopharmaceutical classification system, solubility, permeability, bioavailability, bioequivalence, regulatory biowaivers
